

Figure S1. Tornado diagrams. Results of a one-way sensitivity analysis of first-line osimertinib group and (A) second-line osimertinib group in China, (B) standard group in China, (C) second-line osimertinib group in the United States, (D) standard group in the United States. Results of a one-way sensitivity analysis of osimertinib-company donation group, (E) erlotinib-health insurance group as first-line therapy in China and (F) gefitinib-health insurance group as first-line therapy in China.




Figure S1. Continued. Results of a one-way sensitivity analysis of osimertinib-company donation group, (G) gefitinib-company donation group as first-line therapy in China, (H) icotinib-health insurance group as first-line therapy in China and (I) icotinib-company donation group as first-line therapy in China. U, utility in first-line osimertinib group; X, utility in standard group or second-line osimertinib group; C, cost in first-line osimertinib group; D, cost in standard group or second-line osimertinib group; PFS, progression-free survival; PD, progressive disease; EV, earned value. XPFS: Utility of progression-free survival state in second-line osimertinib group (A and C) or standard group (B, D-H). XPFS2: Utility of progression-free survival state in second-line osimertinib group. XPD1: Utility of the state after second disease progression in second-line osimertinib group. XPD: Utility of progressive disease state in standard group. UPFS: Utility of progression-free survival state in first-line osimertinib group. UPD: Utility of progressive disease state in first-line osimertinib group. DPFS2: Cost of progression-free survival state in second-line osimertinib group (A and C) or standard group (B, D-H). DPFS: Cost of progression-free survival state in second-line osimertinib group. DPD1: Cost of the state after second disease progression in second-line osimertinib group. DPD: Cost of progressive disease state in standard group. CPFS: Cost of progression-free survival state in first-line osimertinib group. CPD: Cost of progressive disease state in first-line osimertinib group.




Figure S2. Cost-effectiveness acceptability curves. Cost-effective acceptability curve for first-line osimertinib group and (A) standard group in China (A) in the United States (B). EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; CE, cost effectiveness.

